Belgium: Defensive actions in UPC and national courts

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Belgium: Defensive actions in UPC and national courts

The opt‐out possibility offered by Article 83 UPCA pays lots of attention to the choices patentees are facing with regards to their filing strategy. We focus here on defensive strategies in the new legislative framework, in particular on actions before national courts.

Coexistence between the UPC and national jurisdictions during the transitional period is governed by the UPCA and by the Brussels Regulation (Recast) (EU) 1215/2012.

Article 83.3 UPCA establishes the right to opt‐out (completely) of the UPC.

Article 83.4 UPCA further stipulates that unless an action has already been brought before a national court, proprietors of or applicants for European patents who made use of the opt‐out in accordance with paragraph 3 shall be entitled to withdraw their opt‐out at any moment.

Thus, if an invalidity action before a national court exists, patentees will not be able to use the UPC at all, including an infringement action.

Is such a legal effect compatible with the Brussels Regulation? Not sure. It is true that under the Regulation, the court first seized retains jurisdiction when the same action, involving the same parties, is subsequently filed in another EU court. Consequently, the existence of an invalidity action in a national court should not prevent the use of the UPC for an infringement action.

In any event, Article 83 deals with the specific opt‐out context. But what about the more general context, namely the impact of an existing action before a national court, where no opt‐out has been requested?

Furthermore, what is the impact of actions before national courts pending at the time of the UPC inception?

These uncertainties make it difficult for parties to implement a defensive strategy. Is it worth investing in an invalidity action in a national court, before entry into force of the UPC? Assuming such an action impacts patentees' choices at all, will it completely prevent the use of the UPC or only preclude the use of the UPC for a nullity action?

Canonici

Jean‐Jacques Canonici


Gevers & OresHolidaystraat, 5B-1831 Diegem - BrusselsBelgiumTel: +32 2 715 37 11Fax: +32 2 715 37 00www.gevers.eu

more from across site and SHARED ros bottom lb

More from across our site

Licensing chief Patrik Hammarén also reveals that the company will rename its IPR business to better reflect its role in defining standards
The acquisition of Pecher & Partners follows the firm’s earlier expansion into litigation to create a ‘one-stop shop’
News of Via Licensing Alliance launching its first semiconductor patent pool and INTA electing a new president were also among the top talking points
Submit your nominations to this year's WIBL Americas Awards by January 23
The 2026 Life Sciences EMEA Awards is now open for entries. We are looking forward to reviewing and celebrating the industry's most impressive achievements and landmarks from the past year.
The tie-up between Perkins Coie and Ashurst may generate some striking numbers, but independent IP firms need not worry yet, according to practitioners
Perkins Coie’s US patent prosecution strength could provide Ashurst with an opportunity to enter an untapped market in Australia, but it may not be easy
Mitesh Patel at Reed Smith outlines why the US Copyright Office and courts have so far dismissed AI authorship and how inventors can protect AI-generated works
Xia Zheng, founder of AFD China, discusses balancing legal work with BD, new approaches to complex challenges, and the dangers of ‘over-optimism’
A dispute involving semiconductor technology and a partner's move from Hoffman Eitle to Hoyng Rokh Monegier were also among the top talking points
Gift this article